Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMPD1 | P17405 | 2/20 | 0.30 |
| ▸ | FBP1 | P09467 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13912378 | 1.00 | SMPD1 (0.30) | SMPD1FBP1 | |
| SCHEMBL13830290 | 0.95 | FBP1 (0.33) | FBP1 | |
| SCHEMBL10005831 | 0.87 | FBP1 (0.34) | SMPD1FBP1 | |
| SCHEMBL21202641 | 0.87 | FBP1 (0.34) | SMPD1FBP1 | |
| SCHEMBL10051004 | 0.87 | FBP1 (0.34) | SMPD1FBP1 | |
| SCHEMBL15964500 | 0.87 | SMPD1 (0.31) | SMPD1FBP1 | |
| SCHEMBL12458447 | 0.86 | FBP1 (0.33) | FBP1 | |
| SCHEMBL21202645 | 0.85 | SMPD1 (0.30) | SMPD1FBP1 | |
| SCHEMBL21474777 | 0.85 | SMPD1 (0.30) | SMPD1FBP1 | |
| SCHEMBL12523685 | 0.85 | SMPD1 (0.41) | SMPD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170268006-A1 | TOLL-LIKE RECEPTOR 9 ANTAGONIST AND METHODS OF USE THEREOF | IDERA PHARMACEUTICALS INC (US) | 2017-09-21 | — | — | US | disclosed |
| US-20120289691-A1 | PROTECTED MONOMER AND METHOD OF FINAL DEPROTECTION FOR RNA SYNTHESIS | AGILENT TECHNOLOGIES, INC. (US) | 2012-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170268006-A1 | TOLL-LIKE RECEPTOR 9 ANTAGONIST AND METHODS OF USE THEREOF | TLR9, TLR3, TLR7 | SMPD1 1059/4885FBP1 2766/4885 |
| US-20120289691-A1 | PROTECTED MONOMER AND METHOD OF FINAL DEPROTECTION FOR RNA SYNTHESIS | NSUN2, SNRPB2, RNGTT | SMPD1 4326/4885FBP1 2059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.